TXMD

TherapeuticsMD, Inc.

$1.74

2.96%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Source: Yahoo Finance
Q-Score49/ 100
Market Cap$20.1M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta0.64
AI summary

Price & performance

1M-15.5%
3M-15.9%
YTD+5.5%
1Y+28.9%
52-week range—
Beta0.64
Full chart and returns against a benchmark

Q-Score

49/ 100

Quality against peers; 50 is the peer median.

Growth50
Risk49
Performance49
Valuation70
Profitability47
Leverage26
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$3M+71.6%
Net income-$569K
Net margin-18.8%+105.0 pts
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtMar 30, 2026
Late filing noticeApr 1, 2026
Auditor changeJan 21, 2026
Filings, findings and the timeline

Revenue exposure

41%of revenue from outside the US
United States59%
Non Us41%
Regions, segments, customers and suppliers

Valuation

TXMDIndustryP/E—35.25P/S6.162.74EV/EBITDA—16.35P/B0.742.46PEG—0.87
Dividend yield0.00%
Every valuation metric